Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Robotic-Assisted Lung Surgery Improves Patient Outcomes

By HospiMedica International staff writers
Posted on 28 Nov 2013
A new study claims that robotic-assisted lobectomy is associated with significantly lower death rates, lower overall complication rates, and shorter hospital stays when compared to open surgery. More...


Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School (Boston, MA, USA) reviewed US state inpatient databases (SIDs) from 2008 to 2012, identifying 33,095 patients in eight states who underwent open surgery (20,238 patients), video-assisted thoracic surgery (VATS, 12,427 patients), or robotic-assisted surgery (430 patients) to remove diseased lung tissue. Patients who underwent segmentectomy were also included. A comparison of outcomes was performed using a propensity-matched analysis.

The results showed that compared to traditional open surgery, robotic-assisted surgery was associated with a significantly reduced mortality (0.2% versus 2%), shorter hospital stays (5.9 days versus. 8.2 days), and a lower overall complication rate (43.8% versus. 54.1%). The results also indicated that the death rate, length of hospital stays, and overall complication rate for robotic-assisted surgery were similar to or better than VATS, but none of the differences were statistically significant. The study was published in the October 2013 issue of the Annals of Thoracic Surgery.

“Case volume for robotic pulmonary resections has increased significantly during the study period, and thoracic surgeons have been able to adopt the robotic approach safely,” concluded lead author Michael Kent, MD, and colleagues of division of thoracic surgery and interventional pulmonology. “Robotic resection appears to be an appropriate alternative to VATS and is associated with improved outcomes compared with open thoracotomy.”

Lobectomy of the lung is performed in early stage non-small-cell lung cancer (NSCLC) patients; it is not performed on patients that have lung cancer that has metastasized to other parts of the body. Tumor size, type, and location are other major factors as to whether a lobectomy is to be performed.

Related Links:

Beth Israel Deaconess Medical Center and Harvard Medical School



Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.